124 related articles for article (PubMed ID: 25837675)
1. MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.
Muñoz-Galván S; Gutierrez G; Perez M; Carnero A
Mol Cancer Ther; 2015 Jun; 14(6):1454-65. PubMed ID: 25837675
[TBL] [Abstract][Full Text] [Related]
2. MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
Ferrer I; Quintanal-Villalonga Á; Molina-Pinelo S; Garcia-Heredia JM; Perez M; Suárez R; Ponce-Aix S; Paz-Ares L; Carnero A
J Exp Clin Cancer Res; 2018 Aug; 37(1):195. PubMed ID: 30119639
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1).
Perez M; Peinado-Serrano J; Garcia-Heredia JM; Felipe-Abrio I; Tous C; Ferrer I; Martin-Broto J; Saez C; Carnero A
Oncotarget; 2016 Oct; 7(41):67033-67046. PubMed ID: 27563810
[TBL] [Abstract][Full Text] [Related]
4. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
5. Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Wu T; Chen W; Zhong Y; Hou X; Fang S; Liu CY; Wang G; Yu T; Huang YY; Ouyang X; Li HQ; Cui L; Yang Y
Mol Cancer Ther; 2017 Apr; 16(4):717-728. PubMed ID: 27903750
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract][Full Text] [Related]
7. MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival.
Perez M; Praena-Fernandez JM; Felipe-Abrio B; Lopez-Garcia MA; Lucena-Cacace A; Garcia A; Lleonart M; Roncador G; Marin JJ; Carnero A
PLoS One; 2013; 8(2):e56169. PubMed ID: 23418532
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.
Kao C; Chao A; Tsai CL; Chuang WC; Huang WP; Chen GC; Lin CY; Wang TH; Wang HS; Lai CH
Cell Death Dis; 2014 Nov; 5(11):e1510. PubMed ID: 25375375
[TBL] [Abstract][Full Text] [Related]
9. The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
Garcia-Heredia JM; Lucena-Cacace A; Verdugo-Sivianes EM; Pérez M; Carnero A
Clin Cancer Res; 2017 Jul; 23(14):3871-3883. PubMed ID: 28153862
[No Abstract] [Full Text] [Related]
10. MAP17 enhances the malignant behavior of tumor cells through ROS increase.
Guijarro MV; Leal JF; Blanco-Aparicio C; Alonso S; Fominaya J; Lleonart M; Castellvi J; Ramon y Cajal S; Carnero A
Carcinogenesis; 2007 Oct; 28(10):2096-104. PubMed ID: 17548903
[TBL] [Abstract][Full Text] [Related]
11. The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D; Palumbo C; Dalla Palma B; Ferretti M; Bolzoni M; Marchica V; Sena P; Martella E; Mancini C; Ferri V; Costa F; Accardi F; Craviotto L; Aversa F; Giuliani N
J Bone Miner Res; 2016 Apr; 31(4):815-27. PubMed ID: 26551485
[TBL] [Abstract][Full Text] [Related]
12. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
13. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
[TBL] [Abstract][Full Text] [Related]
14. Halting pro-survival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients.
Frassanito MA; De Veirman K; Desantis V; Di Marzo L; Vergara D; Ruggieri S; Annese T; Nico B; Menu E; Catacchio I; Ria R; Racanelli V; Maffia M; Angelucci E; Derudas D; Fumarulo R; Dammacco F; Ribatti D; Vanderkerken K; Vacca A
Leukemia; 2016 Mar; 30(3):640-8. PubMed ID: 26487273
[TBL] [Abstract][Full Text] [Related]
15. CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.
Tang H; Xu L; Cen X; Yang L; Feng J; Li G; Zhu H; Gao S; Yu Y; Zhao Y; Tian Z; Hou L; Yu S; Gao G
Int J Mol Med; 2020 Jun; 45(6):1661-1672. PubMed ID: 32236619
[TBL] [Abstract][Full Text] [Related]
16. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
17. p38α limits the contribution of MAP17 to cancer progression in breast tumors.
Guijarro MV; Vergel M; Marin JJ; Muñoz-Galván S; Ferrer I; Ramon y Cajal S; Roncador G; Blanco-Aparicio C; Carnero A
Oncogene; 2012 Oct; 31(41):4447-59. PubMed ID: 22266858
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
19. IKK inhibition increases bortezomib effectiveness in ovarian cancer.
Singha B; Gatla HR; Phyo S; Patel A; Chen ZS; Vancurova I
Oncotarget; 2015 Sep; 6(28):26347-58. PubMed ID: 26267322
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
